| dc.contributor.author | Şahan C. | |
| dc.contributor.author | Öztürk M. | |
| dc.date.accessioned | 2020-06-21T09:14:41Z | |
| dc.date.available | 2020-06-21T09:14:41Z | |
| dc.date.issued | 2003 | |
| dc.identifier.issn | 1300-2996 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/2473 | |
| dc.description.abstract | The potential hepatotoxicity from cancer chemotherapy may be complex. Liver injury during cancer chemotherapy may not always reflect hepatotoxic anticancer drugs; the clinician must also consider reactions to antibiotics, analgesic, antiemetic other medications. Preexisting medical problems, tumor, immumosuppression, hepatitis viruses and other infections and nutrition deficiencies all may affect a host susceptibility to liver injury. Drugs that commonly produce hepatotoxicity are L-asparaginase, methotrexate, cytrabine, 6-thiopurines and mitramycin. The review discusses the effect of chemotherapeutic agents on the liver. | en_US |
| dc.language.iso | tur | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Cancer | en_US |
| dc.subject | Chemotherapeutic agents | en_US |
| dc.subject | Hepatotoxicity | en_US |
| dc.title | Cancer chemotherapy and liver | en_US |
| dc.title.alternative | Kanser kemoterapisi ve karaciğer | en_US |
| dc.type | article | en_US |
| dc.contributor.department | OMÜ | en_US |
| dc.identifier.volume | 20 | en_US |
| dc.identifier.issue | 1 | en_US |
| dc.identifier.startpage | 47 | en_US |
| dc.identifier.endpage | 60 | en_US |
| dc.relation.journal | Ondokuz Mayis Universitesi Tip Dergisi | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
